The results of this first-in-human study of CAN-3110 demonstrate a median overall survival that was substantially longer than the six to nine months typically observed in recurrent high-grade glioma as well as a favorable safety profile.

• Privacy Policy 

Social

• LinkedIn

• Twitter

• Wiki

Scholar

• Google Scholar

• Pub Med